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Abstract
Wnt/B-catenin signaling plays an important role in nor-
mal development. However, its aberrant activation is
associated with several cancers. The aim of this study
is to examine the Wnt/B-catenin pathway in patients
with advanced pancreatic adenocarcinoma (n = 31).
Paraffin sections from tumors (n = 16) and normal pan-
creata (n = 3) were used to determine the localization
of B-catenin. An additional 15 frozen tumors, adjacent
normal pancreata (n = 5), or normal pancreata (n = 4)
were utilized for protein isolation. Tumors were also
examined for mutations in exon 3 of the CTNNB1 gene.
More than 65% of the tumors showed an increase in
total B-catenin, consistent with its enhanced membra-
nous, cytoplasmic, and nuclear localization, but only
two showed mutations in CTNNB1. The majority of the
remaining tumors demonstrated concurrent increases
in Wnt-1 and frizzled-2 (positive regulators) and a
decrease in Ser45/Thr41-phospho-B-catenin. Electro-
phoretic mobility shift assay demonstrated B-catenin–
T-cell factor binding in tumors only. Adenomatous
polyposis coli and axin, which are both negative
regulators, remained unchanged. Unexpectedly, total
glycogen synthase kinase-3B protein was elevated in
these tumors. Elevated levels of E-cadherin were also
observed, although E-cadherin–B-catenin association
in tumors remained unaffected. Thus, Wnt/B-catenin
activation was observed in 65% of pancreatic adeno-
carcinomas, independently of B-catenin gene muta-
tions in most tumors.
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Background
Pancreatic adenocarcinoma is among the most devastating
cancers. It is responsible for 5% to 6% of all cancer-related
deaths and has recently replaced prostate as the fourth
major cause of cancer-related mortality in the United States
[1]. It remains a disease of poor prognosis with a 5-year survival
rate of <4%, which has remained unchanged in the last four
decades [2]. The poor prognosis of pancreatic cancer man-
dates the exploration of potential mechanisms that might con-
tribute to the pathogenesis of this disease and its resistance
to therapy.
The Wnt/b-catenin pathway has been implicated in tumori-
genesis at several sites, including the colon, rectum, lung, skin,
breast, and liver [3–7]. Aberrant signaling involving stabiliza-
tion of b-catenin, along with its nuclear translocation, and acti-
vation of target genes such as c-myc and cyclin D1 have been
observed in these cancers [8,9]. This pathway has also been
shown to be involved in normal development and tissue re-
generation [10,11].
Recent studies have also established a developmental re-
lationship between the pancreas and the liver [12]. There ap-
pears to be a common stem cell that forms a ventral pancreas
or a primitive liver on appropriate signaling. This suggests that
some molecular signals may be shared by the liver and the
pancreas during development and, thus, also in cancer. A
significant number of hepatoblastomas and hepatocellular
cancers have demonstrated aberrant b-catenin accumulation
and signaling [13]. Some pediatric pancreatic tumors, such
as pancreatoblastomas, have also shown such abnormal re-
activity [14,15]. Although there have been some analyses of
this pathway in pancreatic adenocarcinoma through immuno-
histochemistry, reports have been conflicting [16,17].
The Wnt/b-catenin pathway is regulated transcriptionally
and posttranscriptionally. Its central component, b-catenin, is
phosphorylated in the inactive phase of this pathway in the
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absence of Wnt or in the presence of Wnt inhibitors [18,19].
This results in the phosphorylation of b-catenin by glycogen
synthase kinase-3b (GSK3b) or casein kinases. With the
aide of adenomatous polyposis coli (APC) gene product and
axin, it is presented to b-transducin repeat-containing pro-
tein for proteosomal degradation. In the presence of Wnt
or frizzled upregulation, or due to mutations affecting exon 3
of the b-catenin gene (CTNNB1) that impact the Ser/Thr sites
of b-catenin, or APC or axin, b-catenin protein becomes
stable and translocates to the nucleus to turn on target
gene expression. In the present study, we investigate the
status of Wnt/b-catenin pathway and identify this novel mo-
lecular aberration and its mechanism in pancreatic adeno-
carcinoma patients.
Methods
Patient Tissue
All tissues and materials used in this study were obtained
under an approved Institutional Review Board (exempt) pro-
tocol. Paraffin sections from the pancreatic adenocarcinoma
of 16 patients (T1–T16) and three normal pancreatic sec-
tions (N1–N3) were obtained from the Department of Pathol-
ogy, School of Medicine, University of Pittsburgh (Pittsburgh,
PA; n = 10) and the Department of Pathology and Gastro-
enterology, Dayanand Medical College and Hospital (Ludhi-
ana, Punjab, India; n = 6). Relevant patient information and
tumor histology are presented in Table 1. Frozen tissues from
15 additional patients, along with adjacent normal pancreata
in five cases and four independent normal autopsy speci-
mens of pancreata, were obtained from the Department of
Pathology Tissue Bank, School of Medicine, University of
Pittsburgh, and the Cooperative Human Tissue Network,
Eastern Division (Philadelphia, PA). Pertinent patient and
tumor information, along with examined controls, is de-
tailed in Table 2 (FT1–FT15). The tumor–node–metastasis
(TNM) status of three tumors was not available, and one
tumor was classified as T4N0Mx due to recurrence in the
pancreas and soft tissue involvement.
Histology and Immunohistochemistry
Paraffin sections from tumors (n = 16) and normal human
pancreata (n = 3) were used for immunohistochemical stain-
ing. Sections were passed through a sequence of xylene
and graded alcohol and then rinsed in phosphate-buffered
saline (PBS). Endogenous peroxidase was inactivated using
3%hydrogen peroxide (Sigma, St. Louis,MO). Sectionswere
placed in blue blocker (Shandon Lipshaw, Pittsburgh, PA)
then incubated for 2 hours at room temperature with a pri-
mary antibody (diluted to 2.5–5 mg/ml in PBS) that also
contains 1 mg/ml bovine serum albumin (BSA). Slides were
placed in the microwave on high power twice for 10 minutes
in citrate buffer. For each successive step, four 5-minute
rinses in PBS were performed. The sections were incu-
bated in PBS containing an appropriate secondary antibody
(Chemicon, Temecula, CA) for 1 hour at room temperature.
The signal was detected using the ABC Elite kit (Vector
Laboratories, Burlingame, CA), as prescribed in the manu-
facturer’s instructions. Color development was closely moni-
tored under amicroscope. Sections were counterstained with
modified Harris hematoxylin solution (Sigma). Following de-
hydration, by passage through graded alcohol concentra-
tions and xylene, sections were coverslipped and mounted
using DPX (Fluka Laboratories, St. Louis, MO). For negative
control, the sections were incubated with secondary anti-
bodies only. Slides were viewed on an Axioskop 40 (Zeiss,
Thornwood, NY) upright research microscope, and digital
images were obtained by a Nikon Coolpix camera (Nikon,
Melville, NY). Collages were prepared using Adobe Photo-
shop software (Adobe, San Jose, CA).
Genomic DNA Preparation and Mutational Analysis
Genomic DNA was extracted using DNAzol reagent (Mo-
lecular Research Center, Inc., Cincinnati, OH). The DNAwas
dissolved in 20 ml of 10 mM Tris–HCl (pH 8.0). To amplify the
Table 1. Patient Data (for Immunohistochemistry Analysis).
Patient
Number
Age Range
(years)
Sex Tumor Histology TNM
Classification
Anatomic Location
T1 60–69 M Moderately differentiated adenocarcinoma, invasive T3N1Mx Entire length
T2 40–49 M Moderately differentiated adenocarcinoma, invasive T3N1Mx Head
T3 70–79 M Moderately differentiated adenocarcinoma, invasive T3N0Mx Distal/tail
T4 60–69 M Moderately differentiated adenocarcinoma, invasive T3N1Mx Head
T5 70–79 F Moderately differentiated adenocarcinoma, invasive T3N1Mx Head
T6 80–89 M Moderately differentiated adenocarcinoma, invasive T3N1Mx Distal/tail
T7 50–59 F Poorly differentiated adenocarcinoma, invasive T3N1Mx Head
T8 70–79 F Poorly differentiated adenocarcinoma, invasive T3N1Mx Head
T9 70–79 F Moderately differentiated adenocarcinoma, infiltrative T2N0Mx Ampulla of Vater
T10 70–79 M Poorly differentiated adenocarcinoma, invasive T3N0Mx Head
T11 50–59 M Moderately differentiated adenocarcinoma NA Head
T12 40–49 F Moderately differentiated adenocarcinoma NA Body
T13 40–49 M Moderately differentiated adenocarcinoma, invasive NA Head
T14 60–69 M Moderately differentiated adenocarcinoma NA Head
T15 40–49 F Moderately differentiated adenocarcinoma NA Head
T16 40–49 F Moderately differentiated adenocarcinoma NA Head
M, Male; F, female.
280 Wnt/B-Catenin in Pancreatic Tumors Zeng et al.
Neoplasia . Vol. 8, No. 4, 2006
exon 3 of the human b-catenin (CTNNB1) gene, polymerase
chain reaction (PCR) was performed using hCat-E3-S2 sense
primer (5V-CCCTGGCTATCATCTGCTTT-3V) and hCat-E3-
AS2 antisense primer (5V-CACTCACTATCCACAGTT-
CAGCA-3V). The amplified product of 545 bp also included
a 230-bp fragment of CTNNB1’s exon 3. The thermal cycler
was programmed as follows: initial denaturation at 94jC for
2 minutes and 35 amplification cycles for the first PCR; one
amplification cycle comprising denaturationat 94jC for 30 sec-
onds, annealing at 58jC for 30 seconds, and extension at
72jC for 1 minute; and the final extension at 72jC for 10 min-
utes. PCR products were confirmed by agarose gel electro-
phoresis, purified using QIAquick Gel Extraction Kit (Qiagen,
Valencia, CA), and submitted to direct sequencing using the
ABI Big Dye Terminator Cycle Sequencing kit (Applied Bio-
systems, Foster City, CA) and the primers used for PCR.
Whole Cell Lysate Preparation
Frozen tumors (n = 15) and all normal controls (in Table 2)
were utilized for total cell lysate preparation. Homogenization
tubes were initially filled with 200 ml of RIPA buffer (9.1 mM
dibasic sodium phosphate, 1.7 mMmonobasic sodium phos-
phate, 150 mM sodium chloride, 1% Nonidet P-40, 0.5%
sodium deoxycholate, and 0.1% sodium dodecyl sulfate,
pH adjusted to 7.4). A fresh protease and phosphatase in-
hibitor cocktail was also added (Sigma). To determine the
protein concentration of the lysates, a bicinchoninic acid
protein assay was performed, with BSA as standard.
Gel Electrophoresis and Western Blot Analysis
All data shown are representative of three determinations.
Ready gels (7.5%, in 50-ml wells) were loaded with 100 mg of
protein from prepared cell lysates using the mini-PROTEIN
3 electrophoresis module assembly (Bio-Rad, Hercules,
CA). Protein was transferred overnight (0.09 A, 4jC) to
Immobilon-PVDF membranes (Millipore, Bedford, MA) with
the Mini Trans-Blot Electrophoretic Transfer Cell (Bio-Rad)
in transfer buffer (25 mM Tris pH 8.3, 192 mM glycine, 20%
methanol, and 0.025% sodium dodedyl sulfate). Depending
on the antibody, blots were then blocked for 1 hour in either
5% nonfat dry instant milk or 5% BSA, both in Tris-buffered
saline–Tween. Next, blots were incubated with primary anti-
body for 3 hours at room temperature or overnight at 4jC.
Following incubation, blots were washed for 5 minutes (3) in
1%milk blotto/1% BSA. One-hour incubation with horseradish
peroxidase (HRP)–conjugated secondary antibody in 1%milk
blotto/1% BSA took place after the washes. Another series of
washes was administered (3  5 minutes) before blots were
subjected to fresh Super-Signal West Pico Chemiluminescent
Substrate (Pierce, Rockford, IL) for exactly 5 minutes. The
Table 2. Patient Data (for Frozen Tissue Analysis).
Number Age Range
(years)
Sex Histology TNM Tumor Location Control (Label)
FT1 70–79 F Moderately differentiated adenocarcinoma,
invasive
T3N1Mx Head Adjacent normal pancreas (FN1)
FT2 50–59 M Poorly differentiated adenocarcinoma,
invasive
T3N1Mx Distal/tail Adjacent normal pancreas (FN2)
FT3 80–89 M Moderately differentiated adenocarcinoma,
invasive
T4N0Mx Distal/tail Adjacent normal pancreas (FN3)
FT4 70–79 F Moderately to poorly differentiated
adenocarcinoma, invasive
T2N0Mx Head Adjacent normal pancreas (FN4)
FT5 70–79 F Moderately to poorly differentiated
adenocarcinoma, invasive
T3N1M1 Uncinate
process/head
Adjacent normal pancreas (FN5)
FT6 50–59 M Moderately differentiated adenocarcinoma,
invasive
Unavailable Head No adjacent available (N1–N4)
FT7 70–79 M Moderately differentiated adenocarcinoma,
invasive
Unavailable Head Adjacent normal stomach (N7)
FT8 70–79 F Poorly differentiated adenocarcinoma,
invasive
Unavailable Distal/tail Adjacent normal spleen (N8)
FT9 60–69 F Moderately differentiated adenocarcinoma T2N1Mx Head No adjacent available (N1–N4)
FT10 60–69 F Moderately differentiated adenocarcinoma T3N0Mx Head (distalmost
margin)
No adjacent available (N1–N4)
FT11 60–69 M Moderately differentiated adenocarcinoma,
invasive
T3N1Mx Distal/tail No adjacent available (N1–N4)
FT12 50–59 M Moderately to poorly differentiated
adenocarcinoma
T3N0Mx Distal/hilum No adjacent available (N1–N4)
FT13 60–69 F Moderately differentiated adenocarcinoma T2N0Mx Tail No adjacent available (N1–N4)
FT14 50–59 F Moderately differentiated adenocarcinoma T4N0Mx Head No adjacent available (N1–N4)
FT15 60–69 M Poorly differentiated adenocarcinoma T1N0Mx Distal No adjacent available (N1–N4)
Number Age (years) Sex Cause of Death Histology (Pancreas) Medical History
N1 40–49 M Acute renal failure Normal Not significant, nonsmoker, social drinker
N2 70–79 M Acute myocardial infarction Normal Not significant, proton pump inhibitors, nonsmoker,
nonalcoholic
N3 80–89 F Atherosclerotic vascular disease Normal Memory loss, no other significant history, no significant
history of smoking/alcohol intake
N4 80–89 F Not determined/dementia Normal Dementia, memory loss, nonsmoker/nonalcoholic
M, Male; F, female; FT, frozen pancreatic tumors; FN, frozen adjacent normal pancreas; N1–N4, true normal pancreata from autopsies.
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blots were then visualized by autoradiography. Once scanned,
densitometric analysis was employed on the autoradiographs
by means of an NIH Imager software (Bethesda, MD). IgG
elution buffer (Pierce) was used at room temperature (two
30-minute washes) to strip the blots for reprobing.
Primary antibodies utilized in this study were against
b-catenin, E-cadherin, frizzled-1/2, GSK3b, APC, axin, cyclin
D1, and c-myc (Santa Cruz Biotechnology, Santa Cruz, CA);
Wnt-1 (Upstate Biotechnology, Lake Placid, NY); Ser45/
Thr41–b-catenin and Ser33,37/Thr41–b-catenin (Cell Sig-
naling, Beverly, MA); and actin (Chemicon). HRP-conjugated
secondary antibodies (Chemicon) were utilized at 1:50,000
or 1:75,000 dilutions.
Immunoprecipitation
Five hundred micrograms of protein lysate from tumor
and normal samples was brought to a volume of 1 ml using
RIPA buffer and precleared by employing appropriate control
IgG along with 20 ml of Protein A/G agarose (Santa Cruz
Biotechnology). Following overnight end-over-end rotation in
a cold room (4jC), the samples were centrifuged to form a
pellet. The obtained supernatant was then transferred to
a new set of 1.5-ml tubes. Twenty microliters of agarose-
conjugated goat anti–b-catenin antibody (Santa Cruz Bio-
technology) was added, and the tubes were incubated
overnight (4jC). Subsequently, pellets were collected by
centrifugation and subjected to a series of RIPA washes at
4jC followed by centrifugation. The pellets were then resus-
pended in equal volumes of standard electrophoresis loading
buffer with sodium dodecyl sulfate and fresh b-mercapto-
ethanol and boiled for 5 minutes. Lastly, the samples (30 ml
each) were resolved on ready gels and transferred as de-
scribed in Gel Electrophoresis and Western Blot Analysis.
Nuclear Protein Isolation and Electrophoretic Mobility Shift
Assay (EMSA) for -Catenin Activation
Frozen tissues (0.2–0.5 g) from 10 tumors that showed
increases in total b-catenin protein and their respective con-
trols were finely sliced and homogenized in a glass Dounce
homogenizer (50–100 strokes) in 1 ml of hypotonic buffer
[10 mM HEPES pH 7.9, 10 mM NaH2PO4, 1.5 mM MgCl2,
1 mM DTT, 0.5 mM Spermidine, and 1 M NaF, with prote-
ase and phosphatase inhibitor cocktails (P8340, P5726, and
P2850; Sigma) used at 1/100 dilution]. Homogenization was
monitored under a microscope using Trypan blue to con-
trol for the release of nuclei. Homogenates were centri-
fuged for 5 minutes at 800g. Nuclei pellets were washed,
repelleted twice in 2 ml of hypotonic buffer, and snap-frozen
in liquid nitrogen.
Nuclear proteins were extracted in 25 to 50 ml of hyper-
tonic buffer [30 mM HEPES pH 7.9, 25% glycerol, 450 mM
NaCl, 12 mM MgCl2, 1 mM DTT, and 0.1 mM EDTA, with
protease and phosphatase inhibitor cocktails (P8340,
P5726, and P2850; Sigma) used at 1/200 dilution] for 30 to
45 minutes at 4jC with continuous agitation. Extracts were
centrifuged at 30,000g for 30 minutes. Supernatants were
collected, and protein concentration was determined by
bicinchoninic acid assay with BSA as standard.
EMSAwas performed by incubating 5 mg of nuclear protein
(n = 5) extracts with a 32P-end– labeled oligonucleotide
containing the core T-cell factor (TCF)/lymphoid enhancer
factor (LEF) binding site of the cyclin D1 promoter (5V-TGC
CGG GCT TTG ATC TTT GCT-3V) at room temperature for
20 minutes. The binding reaction conditions were 15 mM
HEPES pH 7.9, 75 mM NaCl, 6 mMMgCl2, 0.025 mM EDTA,
2.5 mM Tris pH 7.6, 12.5% glycerol, and 1 mM DTT, with
protease and phosphatase inhibitor cocktails (P8340, P5726,
and P2850; Sigma) used at 1/400 dilution. Reaction products
were analyzed on a 5% nondenaturing polyacrylamide gel
using 0.5% Tris–borate–EDTA buffer. The specificity of the
DNA-binding complex was determined by adding 20 cold
TCF/LEF oligo as competitor. Gels were dried and exposed
to BioMax MR film (Eastman Kodak, Rochester, NY).
Quantitative and Statistical Assessment
Immunohistochemistry was examined by a single pathol-
ogist and scored for b-catenin staining based on intensity. The
staining intensity of b-catenin at the membrane, cytoplasm,
and nuclei of tumor cells (ductal cells), or of ductal cells in
normal samples was scored (1–3) to calculate an arbitrary
immunohistochemical score. Five individual fields (400)
from each section were examined and noted for b-catenin
staining intensity and redistribution in tumor cells or ductal
cells in the tumors and normal pancreata, respectively.
Because of differences in the cellular composition of the
tumors and the normal pancreata, quantitative assessment
excluded differences in the number of positively staining
cells and was chiefly based on the intensity of staining and
the redistribution of b-catenin protein in a single cell type
(ductal cells). Mean ± SEM scores for tumors (n = 16) and
normal samples (n = 3) were averaged and compared for
statistical significance by Student’s t test (P < .05 was con-
sidered significant).
Autoradiographs were scanned and analyzed for densi-
tometry by an NIH Imager 1.58 software. The integrated
optical density (IOD) obtained from this analysis was nor-
malized to the value obtained from normal tissues. Differ-
ences in IOD were represented as fold changes and were
graphically presented using the KaliedaGraph software
(Synergy Software, Reading PA).
Results
Redistribution of -Catenin in Pancreatic Adenocarcinoma
Paraffin sections from pancreatic adenocarcinoma and
normal pancreas were assessed for b-catenin localization. In
the normal pancreas, b-catenin is predominantly localized at
the membrane of the ductal cells in the exocrine pancreas
(Figure 1A). In addition, it is found in the cytoplasm or nucleus
in less than 1% to 3% of these cells.
An overall increase in the intensity of b-catenin staining
was detected in the cytoplasm and nucleus of 11 of 16 tu-
mors (Figure 1, B–G). Interestingly, the membranous local-
ization of b-catenin in all tumor samples remained relatively
intact irrespective of an increase in its cytoplasmic or nuclear
282 Wnt/B-Catenin in Pancreatic Tumors Zeng et al.
Neoplasia . Vol. 8, No. 4, 2006
localization. The remaining five tumors did not exhibit any
change in b-catenin staining in terms of intensity or locali-
zation and were similar to the normal pancreas; one repre-
sentative section is shown (Figure 1H ). For quantitative
assessment, the arbitrary immunohistochemistry score based
on staining intensity at themembrane, cytoplasm, and nucleus
of the ductal cells in the tumors (n = 16) and normal pancreata
(n = 3) showed a statistically significant difference (P < .05;
Figure 2). Eleven of 16 tumors displayed increased staining
for b-catenin (score z 5/9) compared to the normal samples
or tumors that showed no change (score V 2/9) (Table 3).
Thus, an aberrant increase in b-catenin staining was de-
tected in around 68% of pancreatic tumors, suggesting the
activation of the Wnt/b-catenin pathway.
Increased -Catenin Protein in Tumors
Protein lysates from frozen tumors (n = 15) and adjacent
normal pancreata (n = 5) were analyzed for total b-catenin
levels. Ten of 15 tumors showed increased levels of total
b-catenin protein compared to adjacent or true normal con-
trols shown in representative blots (Figure 3A). This increase
ranged from two- to five-fold. Thus, more than 65% of exam-
ined frozen tumors demonstrated a notable increase in total
b-catenin protein by Western blot analysis. The same lysates
Figure 1. -Catenin undergoes redistribution in the majority of pancreatic adenocarcinomas. (A) A representative section from a normal pancreas, obtained
through autopsy, shows predominantly membranous localization in tall columnar acinar cells. Inset: Higher magnification highlights membranous localization (white
arrowhead). (B–G) Representative tumors from six patients show aberrant -catenin localization. Insets: Higher magnification clearly demonstrates increased
nuclear (arrow) and cytoplasmic (arrowhead) -catenin localization in pancreatic adenocarcinoma, while still maintaining membranous localization (white
arrowhead). (H) A representative tumor from the minor subset of tumors shows normal membranous localization of -catenin. Inset: Higher magnification shows
membranous localization (white arrowhead) of -catenin in this tumor.
Wnt/B-Catenin in Pancreatic Tumors Zeng et al. 283
Neoplasia . Vol. 8, No. 4, 2006
were used to determine levels of c-myc and cyclin D1—the
known targets of the Wnt/b-catenin pathway. There was a
small increase in the total c-myc protein in three of six tumors
that displayed an increase in b-catenin protein, whereas the
three others remained unchanged (Figure 3B). Surprisingly,
the two remaining samples that showed no change in total
b-catenin protein also showed a noteworthy increase (greater
than five-fold) in total c-myc protein. A similar pattern was
observed for cyclin D1 levels also, and no direct correlation
was observed in elevated b-catenin and cyclin D1 levels (not
shown). These results suggest a b-catenin– independent
upregulation of c-myc and cyclin D1 in pancreatic adeno-
carcinomas in a significant subset of such tumors.
Increased Nuclear Accumulation and DNA Binding
of -Catenin in Tumors
To verify the increased nuclear accumulation of b-catenin
in tumor samples and to assess its functional relevance, we
isolated nuclear protein extracts from tumors and adjacent
normal tissues and analyzed them for b-catenin protein levels
and DNA binding activity. All 10 samples that showed ele-
vated total b-catenin displayed elevated nuclear b-catenin
protein compared to the controls, as shown in a represen-
tative blot in Figure 3C. In addition, five samples were
randomly selected from these 10 tumors, showing elevated
total and nuclear b-catenin protein b-catenin–TCF complex
formation by EMSA. The b-catenin–TCF complex was read-
ily detected in the nuclear extracts of tumors, as shown in a
representative analysis from tumor 5 and its adjacent normal
pancreas (Figure 3B). These results demonstrate active
b-catenin signaling in pancreatic adenocarcinoma.
Changes in Canonical Wnt/-Catenin Pathway Components
in Tumors
Our next aim was to examine the status of the canonical
Wnt pathway in these tumors to identify additional mecha-
nisms of b-catenin stabilization in pancreatic adenocarcino-
ma. To this end, we investigated the protein expression of
upstream effectors of this pathway: Wnt-1 and frizzled-1/2.
This was dictated by previous reports identifying these genes
in normal pancreata [20,21]. Although low Wnt-1 levels
were detected in normal pancreata, we wanted to exam-
ine its levels in pancreatic adenocarcinomas. Similarly, al-
though frizzled-1 and frizzled-2 were present in normal
pancreata, we were interested in identifying any changes
in tumors. In addition, these components represent the ca-
nonic Wnt pathway. An increase in total Wnt-1 protein was
evident in the same 8 of 10 patients who had demonstrated
elevated b-catenin levels, suggesting a possible mechanism
of b-catenin increase in these patients. Although the ob-
served increase was modest, it was consistently higher in
the tumors compared to controls (Figure 3). In addition,
frizzled-2 demonstrated a bold increase in the same 8 of
10 tumor samples, as shown in representative Western
blot analysis, whereas frizzled-1 remained undetected in
tumors or controls (Figure 3). Next, we examined the tu-
mors and normal tissue lysates for negative regulators of
b-catenin, which are components of its degradation pathway.
GSK3b, axin, and APC proteins were examined in pan-
creatic tumors and adjacent normal pancreata. All tumors
showed an unexpected increase in total GSK3b levels com-
pared to the normal or adjacent controls (Figure 3). Axin
protein levels in the majority of tumors from adjacent or
normal pancreata remained unchanged, whereas a minor-
ity of tumors showed increased levels of axin in tumors,
which coexisted always with increased b-catenin (Figure 3).
APC protein levels also displayed similar levels in tumors
and adjacent normal or true normal pancreata in all cases
(Figure 3). These results indicate that, although GSK3b
elevation might be a compensatory or an unrelated event,
the inability of axin or APC proteins to increase and thus
Figure 2. An approximately five-fold increase in arbitrary immunohisto-
chemical score was observed in pancreatic tumors (n = 16) versus normal
pancreata (n = 3), which was statistically significant (P < .05).
Table 3. Quantitative Estimation of b-Catenin Immunohistochemistry in
Pancreatic Adenocarcinoma Samples.
Number Membrane Cytoplasm Nucleus Overall
T1 ++ +++ ++ 6/9
T2 ++ +++  5/9
T3 ++ +++ + 6/9
T4 ++ ++ + 5/9
T5 +++ +++  6/9
T6 +++ +++ + 7/9
T7 +++ +++ ++ 8/9
T8 + +  2/9
T9 +++ +++ + 7/9
T10 + +  2/9
T11 ++   2/9
T12 +   1/9
T13 ++ ++ + 5/9
T14 +++ +++ ++ 8/9
T15 ++ +++ ++ 7/9
T16 +   1/9
N1 +   1/9
N2 +   1/9
N3 ++   2/9
T1–T16, Paraffin sections from 16 patients; N1–N3, normal pancreas
paraffin sections.
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assist in b-catenin degradation may further contribute to b-
catenin stabilization [22,23].
Coherent Changes in Serine–Threonine Phosphorylation
of -Catenin
To understand the functional significance of the above
changes, we examined the serine–threonine phosphoryla-
tion status of b-catenin in the tumors and adjacent or true
normal pancreata. Once phosphorylated at specific serine
and threonine residues, b-catenin underwent degradation by
ubiquitination [18]. Either Ser33,37/Thr41–phosphorylated
b-catenin levels remained unaffected, or there was a modest
increase in tumors, as shown in a representative blot (Fig-
ure 3). Next, we examined any differences in the levels of
Ser45/Thr41–phosphorylated b-catenin, which was a more
sensitive and rate-limiting step of b-catenin degradation.
A consistent decrease in Ser45/Thr41–phosphorylated b-
catenin was observed in 8 of 10, with elevated total b-catenin
protein tumors compared to normal controls (Figure 3). This
coexisted with increased levels of b-catenin, as well as
Wnt-1 and frizzled, in the tumors. A small subset showed
no change in Ser45/Thr41–phosphorylated b-catenin levels,
despite an observed increase in b-catenin protein. This indi-
cates an additional mechanism of b-catenin stabilization in a
significant number of pancreatic adenocarcinoma (Table 4).
Mutational Analysis of Exon 3 of CTNNB1 (b-Catenin Gene)
Exon 3 mutations in b-catenin gene or CTNNB1 have
been classically associated with many tumors. Our next
step was to examine the mutational status of b-catenin in
the 15 frozen tumor samples. Exon 3 of CTNNB1, whose
product contains the serine and threonine sites essential for
phosphorylation and ubiquitination, was amplified by PCR.
An expected size of product was obtained, ruling out any
deletions as reported in other tumors [9]. The products were
sequenced and examined for mutations. Two of 15 sam-
ples showed clear mutations affecting Ser33 and Ser37,
respectively (Figure 4). These were single basepair alter-
ations resulting in missense mutations. These tumors had
previously shown increased levels of b-catenin protein with-
out any changes in Wnt-1 or frizzled proteins or changes
in Ser33/37/45– or Thr41-phosphorylated b-catenin levels
compared to adjacent or normal pancreata (Table 4). A
normal sequence was obtained from the adjacent normal
pancreas of FT2 (not shown).
E-cadherin and Its Association with -Catenin in Tumors
Another important interaction of b-catenin at the cell mem-
brane is with E-cadherin [24,25]. A representative section
Figure 3. Activation of the Wnt/-catenin pathway in the majority of pancreatic adenocarcinomas. (A) Western blot analysis from four representative tumors that
display increased total -catenin protein compared to their adjacent normal pancreata (upper panel) or independent normal pancreata (lower panel). -Actin
demonstrates comparable loading of proteins. The c-myc protein remains unchanged between tumors and adjacent normal pancreata in the upper panel. (B) A
representative Western blot analysis using nuclear lysates from a tumor that displayed increased total levels of -catenin shows increased nuclear -catenin as
well. EMSA detects the -catenin–TCF complex (arrow) in tumors and not in adjacent normal pancreas in a representative analysis. (C) Representative Western
blot analyses for the status of canonical Wnt pathway in two tumors that display elevated total -catenin reveal elevated Wnt-1 and frizzled-2 in tumors compared to
normal adjacent (left set) or true normal pancreata (right set). No change in axin or APC was detected; however, an unexpected increase in GSK3 was evident in
tumors only. Although Ser33,37/Thr41–phosphorylated -catenin showed either no change (left set) or an increase in tumor (right set) compared to their
respective controls, Ser45/Thr41–phosphorylated -catenin levels were decreased in tumors, again suggesting the stabilization of -catenin as a mechanism of its
increase and activation. -Actin blot shows equal protein loading.
Table 4. Summary of Results of Changes in Canonical Wnt Components
and CTNNB1 Mutations in 15 Frozen Tumor Samples.
Name Total b-Catenin
Protein
Wnt-1/frizzled-2
Protein
Ser45/Thr41
b-Catenin Protein
Mutations in
CTNNB1
FT1 NC NC NC ND
FT2 I NC NC S33Y
(TCT!TAT)
FT3 I I D ND
FT4 I I D ND
FT5 I I D ND
FT6 NC NC NC ND
FT7 I I D ND
FT8 I I D ND
FT9 NC NC NC ND
FT10 NC NC NC ND
FT11 I I D ND
FT12 I I D ND
FT13 NC NC NC ND
FT14 I NC NC S37T
(TCT!ACT)
FT15 I I D ND
FT1–F15, Frozen pancreatic tumor from 15 patients; NC, no change; I, in-
crease; D, decrease; ND, none detected.
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from normal pancreata shows membranous distribution with
minimal subcellular staining (Figure 5A). Analysis of the
tumors revealed increased membranous and cytoplasmic
localization of E-cadherin, as shown in two representative
sections (Figure 5, B and C). These samples demonstrated
increased b-catenin staining at the membrane as well (cor-
responding b-catenin staining is shown in Figure 1, C and D).
Lastly, a representative section of a smaller subset of tumors
is shown, which shows no change in E-cadherin localization
or intensity compared to the normal pancreas (Figure 5D).
Western blot analysis also confirmed an increase in total
E-cadherin protein in the majority of tumors (Figure 6A).
A small subset of tumors showed comparable levels of
E-cadherin in tumors and normal tissues (Figure 6A, right
set). In themajority of tumors with elevated E-cadherin levels,
there was concomitant elevated b-catenin as well. Thus,
overall, most nonmetastatic pancreatic tumors continued
to show membranous E-cadherin localization. Next, the
b-catenin–E-cadherin complex was examined in the tumors.
Previously, the tyrosine phosphorylation of b-catenin has
been shown to not only negatively regulate cell–cell adhe-
sion by affecting the b-catenin–E-cadherin complex, but also
to contribute to cytoplasmic and nuclear b-catenin (activation)
[24,26,27]. No tyrosine phosphorylation on b-catenin was
detected in tumors (Figure 6B). In addition, the continued
association of b-catenin and E-cadherin was evident in all
tumors, as seen in a representative blot (Figure 6B). The as-
sociation was proportional to the amount of b-catenin pulled
down in the immunoprecipitate. Stoichiometric analysis
Figure 4. Missense point mutations in the -catenin gene in pancreatic
tumors in two patients FT2 (upper panel) and FT14 (lower panel). Sequence
analysis shows S33C (A) and S37F (B) mutations.
Figure 5. Continued and increased E-cadherin localization at the membrane in pancreatic tumors. (A) A representative section from normal pancreata shows
membranous localization (arrow) of -catenin with some subcellular stainings. (B and C) Representative analysis from two tumors reveals continued membranous
localization (arrow) of E-cadherin with increased intensity and some cytoplasmic staining as well. (D) A representative section from a tumor shows comparable
E-cadherin localization or intensity at the membrane (arrow) to the control.
Figure 6. Increased E-cadherin level and its continued interaction with -
catenin is observed in pancreatic adenocarcinoma. (A) Two pairs of tumors
and normal pancreata at the upper left panel show increased levels of total E-
cadherin in this representative Western blot analysis. The right pair shows no
change. The bottom panels show -actin as a loading control. (B) A
representative coprecipitation study shows continued -catenin–E-cadherin
association (middle panel) in pancreatic adenocarcinomas in most tumors,
which was a function of immunoprecipitated -catenin in lysates (bottom
panel). No tyrosine phosphorylation of -catenin was detectable (top panel).
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reveals a 15% to 20% association between these pro-
teins. Althoughmost tumors in this studywere nonmetastatic,
we observed a continued association of E-cadherin and b-
catenin in FT5, which was the only metastatic tumor in our
study. Thus, although no changes in b-catenin–E-cadherin
association were observed in pancreatic adenocarcinoma,
both proteins independently demonstrated an increase in the
tumors compared to adjacent or normal pancreata.
Discussion
Aberrations in the Wnt/b-catenin signaling pathway are fre-
quently observed in cancers [28–30]. This pathway is also
crucial in the development of normal tissues, such as the
skin, brain, mammary gland, liver, and others, and regulates
key cellular processes, such as proliferation, apoptosis, and
differentiation [10,31]. More recently, its role has been es-
tablished in pancreatic development as well. Its role in the
development of pancreatic adenocarcinoma is controver-
sial due to the lack of a comprehensive analysis of its com-
ponents in such tumors. One study of a large number of
pancreatic adenocarcinomas failed to detect any mutations
in the CTNNB1 gene or nuclear accumulations of b-catenin
[16]. Other reports of immunohistochemical analysis of
these tumors show a subset with b-catenin accumulation
[17,32]. Although the differences observed could be attrib-
uted to geographic or idiopathic factors, our present study is a
comprehensive analysis of the Wnt/b-catenin pathway in
pancreatic tumors in patients.
Activation of the Wnt/b-catenin pathway may proceed via
several mechanisms. One suchmechanism that brings about
b-catenin stabilization is the presence of mutations in the
genes encoding for b-catenin, axin, or APC, which interfere
with b-catenin phosphorylation and ubiquitination [3,4,8,9].
However, other reports have also demonstrated mutation-
independent accumulation and activation of b-catenin [6].
Such mechanisms, although not fully elucidated, involve
upstream effectors of b-catenin, such as theWnt and frizzled,
or changes in Wnt pathway modulators, such as frizzled-
related proteins, Wnt-inhibitory factor-1, and Dikkopf [33].
Our main goal was to examine any changes in the central
component of the canonical Wnt pathway and then to begin
to address changes in its upstream effectors, especially in
some of the known canonical Wnt and frizzled proteins in the
pancreas. The expression of Wnt and frizzled genes in the
pancreas has been explored [20,21,34]. Wnt-1, a classic
canonical Wnt, is expressed at low levels in normal pan-
creata; thus, its alterations could be readily appreciated. In
addition, although frizzled-1 and frizzled-2 had been reported
in the pancreas as well-known components of the canonical
Wnt pathway, we still wanted to address any changes in these
proteins in cancer. It was beyond the scope of the present
study to examine additionalWnt and frizzled genes and their
products. Yet, another mechanism involved protein–protein
interactions at the cell membrane, which was mediated by
the tyrosine phosphorylation of b-catenin [26,27,35,36].
This study aims to reconfirm some of the earlier immu-
nohistochemical observations concluding the state of the
Wnt/b-catenin pathway in pancreatic adenocarcinoma.
Overall, around 65% of all pancreatic tumors showed acti-
vation of the canonical Wnt/b-catenin pathway, whereas 11
of 16 paraffin samples of pancreatic tumors showed in-
creased b-catenin accumulation in the cytoplasm and nu-
cleus by immunohistochemistry. An additional 10 of 15 frozen
tumors showed an increase in total and nuclear b-catenin
proteins. Interestingly, the levels of c-myc and cyclin D1,
known targets of this pathway, did not correlate with elevated
b-catenin in all cases. This could be due to b-catenin–
independent regulation of these targets, as has been ob-
served in other instances [37–40]. Additionally, an increased
tissue/stage specificity of Wnt targets is being identified, sug-
gesting that c-myc and cyclin D1 might not be pancreas-
specific targets of this pathway as in the liver [41–43].
Although 2 of 10 frozen tumors showed mutations in exon
3 of CTNNB1, the remaining eight tumors demonstrated
elevated levels of Wnt-1 and frizzled-2 proteins. This led
to decreased phosphorylation of b-catenin at Ser45/Thr41
residues in these tumors and to concurring accumulation
and activation of b-catenin. In addition, barring one exception
where the axin protein was elevated (perhaps in a compen-
satory manner) in a tumor, we observed no changes in axin
or APC proteins in the tumors or normal pancreata. This fail-
ure in the increase of total axin or APC proteins in response
to elevated b-catenin levels may further potentiate b-catenin
levels in some patients. In addition, this is relevant because
we did not identify a decrease in total axin, APC, or GSK3b
proteins in the tumors, which would have addressed the
mechanism of b-catenin stabilization in the first place. An
increase in GSK3b appears to be compensatory because the
phosphorylation of b-catenin at Ser45/Thr41 showed a de-
crease, rather than an expected increase. Again, although
the exact mechanism is unclear at this time, increased total
GSK3b protein might not reflect a proportional increase in its
kinase activity, which might not have changed, especially
in the light of the upstream elevated Wnt-1 and frizzled
proteins. An alternative explanation can be that, because
GSK3b is also a key player in several other pathways such
as the insulin, Akt, CREB, and other pathways, the changes
observed in its levels in pancreatic adenocarcinoma (total
increase) could be secondary to the involvement of any of
these pathways [44,45].
b-Catenin–E-cadherin interactions are important in main-
taining cell–cell adhesion and in contributing toward b-catenin
activation [46]. We observed a consistent increase in both
of these proteins in pancreatic tumors. They continued to
associate with each other at the membrane, and no tyrosine
phosphorylation of b-catenin was detected in the tumors,
which was also true in only one metastatic tumor. In addition,
the coexisting increase of both proteins in the cytoplasm
might also be due to dissociation of these proteins as a
complex, as has been reported previously [47]. Although
we cannot rule out selection bias, several locally invasive
and moderately to poorly differentiated tumors continued
to show intact b-catenin–E-cadherin association. Thus,
although our study will not be able to rule out the role of the
b-catenin–E-cadherin complex in pancreatic tumor invasion
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or metastasis, we conclude its insignificant role in contrib-
uting to the free and active b-catenin pool in these tumors.
Thus, all findings of the present study are summarized in
Figure 7 and can be highlighted as follows: 1) an increase in
Wnt-1 and frizzled-2 proteins results in a decrease in b-
catenin serine/threonine phosphorylation and its subsequent
accumulation and nuclear translocation; 2) the failure of in-
crease in b-catenin’s degradation complex proteins, such as
axin andAPC, further promotes b-catenin stabilization; and 3)
there is only minor, if any, contribution of the E-cadherin–b-
catenin complex toward the cytoplasmic pool of b-catenin in
these tumors.
Presently, significant efforts are being directed at synthe-
sizing or identifying inhibitors of key pathways that are
dysregulated in cancers. Research is aimed at using such
inhibitors of several cancer treatments [48–50]. Thus, it is
imperative to identify aberrant signaling pathways in spe-
cific cancers, which can be targeted for therapy. The Wnt/
b-catenin pathway has been discussed previously as a po-
tential therapeutic target [51]. Because we demonstrate
aberrant Wnt/b-catenin activation in around 65% of pancre-
atic adenocarcinomas, there might be a therapeutic role of
b-catenin inhibition in these tumors. Several studies in other
organs, especially the liver, have correlated b-catenin acti-
vation to cell proliferation [22,43]. Although no specific in-
hibitors of the Wnt/b-catenin pathway are available, we and
others have shown the impact of b-catenin inhibition on cell
proliferation in the development of tumors by antisense or
therapeutic agents [52–54]. Interestingly, Gleevec (STI-571;
Novartis, East Hanover, NJ) has been shown to have an
anti–b-catenin effect [55]. Unfortunately, such therapy has
not shown any benefit in pancreatic adenocarcinoma [56].
The results of our present study clearly demonstrate the
reason why it was ineffective in this tumor. As reported by
Zhou et al. [55], Gleevec inhibits tyrosine phosphorylation–
dependent b-catenin activation, which was never observed in
any of the pancreatic tumors analyzed in our study. Thus, this
could be at least one of the mechanisms that contributed to
the failure of this tyrosine kinase inhibitor to prevent pancre-
atic tumor progression in patients. Putting it in perspective,
our results establish the therapeutic advantage of the identi-
fication and use of specific agents in human pancreatic
adenocarcinoma that would promote b-catenin degradation
and decrease its nuclear translocation in a tyrosine phos-
phorylation– independent manner. Unpublished reports in
our laboratory have identified agents such as celecoxib
(Celebrex; Pfizer, New York, NY) and SDX-101 (Salmedix,
Inc., San Diego, CA), which induce such a change and may
be beneficial in tumors that demonstrate elevated b-catenin
levels. This could be one of the factors thatmight contribute to
the therapeutic efficacy of selective COX-2 inhibitors in
preclinical pancreatic tumor studies [57,58].
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